Aesica
Aesica Cramlington site, in Northumberland, UK.Global CMO Aesica has announced a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis. This latest partnership is already the Aesica Innovation Board’s (AIB’s) fourth with an academic institution in less than six months, established to help bridge the growing R&D gap by identifying early stage technologies for development into commercial applications.
Amide bond formation is fundamental in pharmaceutical manufacturing. A recent survey conducted by the Green Chemistry Institute Roundtable identified that amide bond formation was utilised in 84% of a set of drug candidates. The partnership’s aim is to revolutionise traditional amide formation techniques by generating alternative methods for amide bond formation that will be more eco-friendly and chemically versatile. This approach will be commercially available to Aesica customers in the next two to three months and already the company is actively seeking commercial opportunities to work with potential compounds that could benefit from this technology. Aesica envisages this new development helping pharmaceutical companies that encounter problems with amide synthesis and owing to the utilisation of more sustainable reagents, production costs will be lowered whilst offering the potential of higher chemical yields.
The University of Nottingham has a strong track record of world-leading research in green and sustainable chemistry. This collaboration builds upon recently announced plans to establish a Centre of Excellence for Sustainable Chemistry, part-funded by an investment from the Higher Education Funding Council for England (HEFCE) UK Research Partnership Investment Fund. The Centre aims to form creative partnerships with companies like Aesica to develop new chemical-based technologies that minimise environmental impact and are both energy and resource efficient.
The University was confident about the success of this technology on a small-scale basis and was keen to test its robustness in a commercial application. Preliminary studies were undertaken using funds awarded by the Engineering and Physical Sciences Research Council (EPSRC) under the Research Development (Pathways to Impact) Funding Scheme.
“Since realising the initial use of our coupling agent in 2005, one of our goals has been to see this novel technology used in larger scale industrial environments,” said Simon Woodward, Professor of Synthetic Organic Chemistry, University of Nottingham. “We look forward to collaborating with Aesica and seeing the full commercial potential of this novel technology in API manufacture.”
Aesica Pharmaceuticals Ltd, +44 191 218 1960, info@aesica-pharma.com, www.aesica-pharma.com.